GlassScriptPhysician profile
Sarah E Tinsler
NPI 1134484744
$736.92
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $644 · 2020: $92.66.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $212.45 | 2019-2020 | |
| Novo Nordisk INC | $108.02 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $102.62 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $58.11 | 2019-2020 | |
| Pfizer INC. | $50.03 | 2019-2020 | |
| Lilly USA, LLC | $46.06 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $25.29 | 2019 | |
| Glaxosmithkline, LLC. | $24.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.18 | 2019 | |
| Astellas Pharma US INC | $14.98 | 2019 | |
| Allergan, INC. | $12.92 | 2019 | |
| Sanofi Pasteur INC. | $12.72 | 2019 | |
| Ironshore Pharmaceuticals INC. | $12.30 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Tinsler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.